Literature DB >> 7102417

Nimodipine: a new calcium antagonistic drug with a preferential cerebrovascular action.

S Kazda, R Towart.   

Abstract

Nimodipine, isopropyl (2-methoxy-ethyl) 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate, is a new calcium antagonistic vasodilator with a preferential effect on brain vessels. Nimodipine prevents spasm of the isolated rabbit basilar artery produced both by depolarization and by receptor stimulation. In peripheral vessels nimodipine does not inhibit agonistically induced contractions. In vivo nimodipine also dilates predominantly cerebral vessels; peripheral vasodilation resulting in a decrease in blood pressure is much less pronounced. Nimodipine prevents the impaired reperfusion of the brain caused by a transitory global cerebral ischaemia. Nimodipine is predicted to be useful in the prophylaxis and treatment of cerebral vasospasm in humans.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7102417     DOI: 10.1007/BF01728880

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  2 in total

1.  Cerebral arterial spasm: part 10. Reversal of acute and chronic spasm in dogs with orally administered nifedipine.

Authors:  G S Allen; A L Bahr
Journal:  Neurosurgery       Date:  1979-01       Impact factor: 4.654

2.  The selective inhibition of serotonin-induced contractions of rabbit cerebral vascular smooth muscle by calcium-antagonistic dihydropyridines. An investigation of the mechanism of action of nimodipine.

Authors:  R Towart
Journal:  Circ Res       Date:  1981-05       Impact factor: 17.367

  2 in total
  28 in total

Review 1.  Neuroprotection for ischemic stroke: past, present and future.

Authors:  Myron D Ginsberg
Journal:  Neuropharmacology       Date:  2008-03-04       Impact factor: 5.250

2.  An experimental study of the effect of nimodipine in primate subarachnoid haemorrhage.

Authors:  N W Dorsch; N M Branston; R J Harris; P Bentivoglio; L Symon
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

Review 3.  The physiology of cerebral blood flow during cardiopulmonary resuscitation.

Authors:  I D Berkowitz; M C Rogers
Journal:  Can J Anaesth       Date:  1988-05       Impact factor: 5.063

4.  Pharmacological properties of voltage-dependent calcium channels in functional microvessels isolated from rat brain.

Authors:  N Morel; T Godfraind
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

5.  Prevention of vasospasm in subarachnoid haemorrhage. A controlled study with nimodipine.

Authors:  J Philippon; R Grob; F Dagreou; M Guggiari; M Rivierez; P Viars
Journal:  Acta Neurochir (Wien)       Date:  1986       Impact factor: 2.216

6.  A bout analysis reveals age-related methylmercury neurotoxicity and nimodipine neuroprotection.

Authors:  Andrew Nathanael Shen; Craig Cummings; Derek Pope; Daniel Hoffman; M Christopher Newland
Journal:  Behav Brain Res       Date:  2016-05-16       Impact factor: 3.332

7.  [Effect of the Ca antagonist nimodipine on global and regional cerebrovascular circulation].

Authors:  M R Gaab; C P Rode; E H Schakel; I Haubitz; J Bockhorn; A Brawanski
Journal:  Klin Wochenschr       Date:  1985-01-02

8.  Experimental intracerebral haemorrhage: the effect of nimodipine pretreatment.

Authors:  E J Sinar; A D Mendelow; D I Graham; G M Teasdale
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-05       Impact factor: 10.154

9.  Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage.

Authors:  E Vinge; K E Andersson; L Brandt; B Ljunggren; L G Nilsson; S Rosendal-Helgesen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Mitochondrial calcium sequestration in cortical and hippocampal neurons after prolonged ischemia of the cat brain.

Authors:  K A Hossmann; B Grosse Ophoff; R Schmidt-Kastner; U Oschlies
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.